Repurposing Azilsartan medoxomil attenuates periodontitis by targeting SERPINB9 to promote apoptosis of IL1B+ macrophages
International Immunopharmacology · 2026-05 · 177 · 116523
DOI: 10.1016/j.intimp.2026.116523 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-05. Verfasst von Kejia Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthodontics, The Affiliated Stomatological Hospital of Nanjing Medical University, 210029 Nanjing, Jiangsu, China; State Key Laborator…. Hauptthemen laut MEDLINE: Periodontitis, Macrophages, Oxadiazoles, Benzimidazoles. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Jiangsu Provincial Medical Center, National Natural Science Foundation of China, Graduate Research and Innovation Projects of Jiangsu Province.
Abstract (Originalsprache)
Periodontitis (PD) is a common chronic inflammatory disease characterized by progressive destruction of periodontal tissues and is associated with systemic disorders such as diabetes and cardiovascular disease. Despite its high global burden, current diagnostic and therapeutic strategies remain limited, highlighting the urgent need for reliable biomarkers and novel therapeutic targets. Macrophages are central to the pathogenesis of PD. Recent single-cell transcriptomic studies have identified IL1B+ macrophages as a pro-inflammatory subset closely linked to tissue destruction. However, the molecular mechanisms governing their survival remain poorly understood. In this study, we integrated multiple single-cell RNA sequencing datasets from the GEO database and applied five machine-learning algorithms to systematically identify critical regulators among differentially expressed genes in macrophages. SERPINB9 (PI9 in humans, Spi6 in mice) emerged as a key candidate, showing elevated expression in IL1B+ macrophages. Functional validation in vitro and in vivo confirmed that SERPINB9 promotes macrophage survival and sustains inflammatory responses. Furthermore, an in silico drug-repurposing screen based on FDA-approved compounds identified Azilsartan medoxomil as a potential inhibitor of SERPINB9. Pharmacological inhibition of SERPINB9 attenuated inflammatory macrophage responses and alleviated alveolar bone loss in experimental periodontitis, supporting its therapeutic potential. Collectively, these findings reveal a novel programmed cell death-related regulatory mechanism in macrophages, identifying SERPINB9 as a promising biomarker, and suggest that targeting SERPINB9 may offer a clinically translatable therapeutic strategy for periodontitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthodontics, The Affiliated Stomatological Hospital of Nanjing Medical University, 210029 Nanjing, Jiangsu, China; State Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral Dise…
- School of Basic Medical Sciences, Nanjing Medical University, 211166 Nanjing, Jiangsu, China; Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease…
Förderung
- Jiangsu Provincial Medical Center
- National Natural Science Foundation of China
- Graduate Research and Innovation Projects of Jiangsu Province
Zitieren
APA
Zhang, K., Zhao, W., Lin, Y., Sun, X., Zhang, H., & Yan, B. (2026). Repurposing Azilsartan medoxomil attenuates periodontitis by targeting SERPINB9 to promote apoptosis of IL1B+ macrophages. International Immunopharmacology, 177, 116523. https://doi.org/10.1016/j.intimp.2026.116523
Vancouver
Zhang K, Zhao W, Lin Y, Sun X, Zhang H, Yan B. Repurposing Azilsartan medoxomil attenuates periodontitis by targeting SERPINB9 to promote apoptosis of IL1B+ macrophages. International Immunopharmacology. 2026;177:116523. doi:10.1016/j.intimp.2026.116523
BibTeX
@article{Zhang2026,
author = {Zhang, Kejia and Zhao, Weiye and Lin, Yongze and Sun, Xueyu and Zhang, Hanwen and Yan, Bin},
title = {Repurposing Azilsartan medoxomil attenuates periodontitis by targeting SERPINB9 to promote apoptosis of IL1B+ macrophages},
journal = {International Immunopharmacology},
year = {2026},
volume = {177},
pages = {116523},
doi = {10.1016/j.intimp.2026.116523}
}
EUVIMED